Lingaliptin + Dapagliflozin + Metformin SR is a potent combination therapy designed to manage type 2 diabetes mellitus. This triple-action formulation helps control blood sugar levels through complementary mechanisms: Lingaliptin 5mg – a DPP-4 inhibitor that enhances the body’s incretin hormones, increasing insulin secretion and reducing glucagon release. Dapagliflozin 10mg – an SGLT2 inhibitor that promotes glucose excretion through urine, reducing blood sugar levels and aiding weight management. Metformin HCl (SR) 500mg/1000mg – a sustained-release biguanide that decreases hepatic glucose production and improves insulin sensitivity. Together, these three agents offer comprehensive glycemic control, targeting both fasting and postprandial blood sugar levels. The sustained-release Metformin ensures prolonged therapeutic effect with minimized gastrointestinal side effects, improving patient compliance.
